CITANEST

This brand name is authorized in United States. It is also authorized in Malta, Netherlands, New Zealand, Turkey, UK.

Active ingredients

The drug CITANEST contains one active pharmaceutical ingredient (API):

1	Prilocaine UNII MJW015BAPH - PRILOCAINE HYDROCHLORIDE
	Prilocaine is a toluidine derivative and intermediate-acting amino amide with local anesthetic property. Prilocaine binds to the intracellular surface of sodium channels which blocks the subsequent influx of sodium into the cell. Action potential propagation and never function is, therefore, prevented. This block is reversible and when the drug diffuses away from the cell, sodium channel function is restored and nerve propagation returns.
	Read more about Prilocaine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CITANEST PLAIN Solution for injection	MPI, US: SPL/Old	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N01BB04	Prilocaine	N Nervous system → N01 Anesthetics → N01B Anesthetics, local → N01BB Amides
Discover more medicines within N01BB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
GB	Medicines & Healthcare Products Regulatory Agency	56381
MT	Medicines Authority	AA565/30602
NL	Z-Index G-Standaard	14920573, 14920581
NL	Z-Index G-Standaard, PRK	96539, 96547
NZ	Medicines and Medical Devices Safety Authority	773, 775
TR	İlaç ve Tıbbi Cihaz Kurumu	8699874080496
US	FDA, National Drug Code	66312-630